Activation of the Met Kinase Confers Acquired Drug Resistance in FGFR-targeted Lung Cancer Therapy

Oncogenesis - United States
doi 10.1038/oncsis.2016.48
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Ex on 14 Mutant Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

MET Targeted Therapy for Lung Cancer: Clinical Development and Future Directions

Lung Cancer: Targets and Therapy
Oncology
2012English

FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2010English

P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Anti-Met VHH Pool Overcomes MET-targeted Cancer Therapeutic Resistance

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Cancer Research
Cancer ResearchOncology
2016English

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Cancer Research
Cancer ResearchOncology
2017English

Drug Resistance in Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy